ROR1 CAR-T cells therapy (Eureka Therapeutics)

N/A

Report date: 2024/05/13 15:28:39

Base Information

Drug NameROR1 CAR-T cells therapy (Eureka Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEureka Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesEureka Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsOvarian NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A